Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27953880 | 0.83 | PDE5A (0.60) | GBA1CYP1A2CYP3A4ALDH1A1CLK4 | |
| SCHEMBL16183305 | 0.83 | GBA1 (0.49) | GBA1CYP1A2CYP3A4ALDH1A1CLK4 | |
| SCHEMBL2155318 | 0.83 | KMT2A (0.55) | GBA1CYP1A2CYP3A4ALDH1A1CLK4 | |
| SCHEMBL2154644 | 0.80 | ABCG2 (0.56) | CYP1A2CYP3A4ALDH1A1CLK4TSHR | |
| SCHEMBL14359013 | 0.80 | CYP1A2 (0.70) | GBA1CYP1A2CYP3A4ALDH1A1CLK4 | |
| SCHEMBL14727925 | 0.79 | KMT2A (0.51) | CYP1A2CYP3A4ALDH1A1CLK4TSHR | |
| SCHEMBL16183771 | 0.79 | ABCG2 (0.55) | GBA1CYP1A2CYP3A4ALDH1A1CLK4 | |
| SCHEMBL14727483 | 0.78 | ADORA2A (0.36) | CYP3A4 | |
| SCHEMBL14727715 | 0.77 | CCNE2 (0.57) | GBA1CYP1A2CYP3A4ALDH1A1CLK4 | |
| SCHEMBL14358664 | 0.77 | CYP19A1 (0.56) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056207-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2018-06-20 | — | — | EP | disclosed |
| EP-3056207-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| EP-2521549-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| CN-105218516-A | Therapeutic compounds and related methods of use | OTSUKA PHARMA CO LTD | 2016-01-06 | — | — | CN | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| CN-102883723-B | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2015-09-16 | — | — | CN | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| CN-102883723-A | Therapeutic compounds and related methods of use | GALENEA CORP | 2013-01-16 | — | — | CN | disclosed |
| EP-2521549-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011082337-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORP. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | GBA1 304/4885CYP1A2 4552/4885CYP3A4 4815/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | GBA1 853/4885CYP1A2 4619/4885CYP3A4 4805/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | GBA1 304/4885CYP1A2 4552/4885CYP3A4 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.